Determinants of Human Papillomavirus Vaccine Acceptability in Latin America and the Caribbean

Jennifer L. Winkler, Scott Wittet, Rosario M. Bartolini, Hilary M. Creed-Kanashiro, Eduardo Lazcano-Ponce, Karen Lewis-Bell, Merle J. Lewis, Mary E. Penny

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

37 Citas (Scopus)


Prophylactic human papillomavirus (HPV) vaccines provide promise as a key component of future cervical cancer prevention programs in the Latin America and the Caribbean region. The successful introduction and acceptance of these vaccines will depend on a range of factors including awareness of cervical cancer as a problem, affordability of the vaccine, political will, competition with other vaccines, feasibility of vaccine delivery and acceptability of the vaccine among the range of groups who will influence uptake. While existing data about acceptability from Latin America and the Caribbean is scarce, it is clear that health policymakers, providers and the general public lack knowledge about HPV and cervical cancer. Furthermore, they would value more local epidemiologic data related to cervical cancer. Price is currently a major barrier to vaccine acceptability and a priority for advocacy. More research is required in Latin America and the Caribbean to determine what messages and strategies will work in these communities. © 2008 Elsevier Ltd. All rights reserved.
Idioma originalEspañol
EstadoPublicada - 19 ago. 2008
Publicado de forma externa

Citar esto